Charles River Laboratories International, Inc. (NYSE:CRL) Receives $200.79 Average Target Price from Analysts

Shares of Charles River Laboratories International, Inc. (NYSE:CRL) have been given an average recommendation of “Reduce” by the seventeen research firms that are covering the firm, MarketBeat reports. Three analysts have rated the stock with a sell recommendation, thirteen have issued a hold recommendation and one has issued a buy recommendation on the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $200.79.

CRL has been the subject of several recent research reports. Bank of America reduced their price target on Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating for the company in a research note on Friday, December 13th. The Goldman Sachs Group reduced their target price on shares of Charles River Laboratories International from $220.00 to $190.00 and set a “buy” rating for the company in a research report on Thursday, January 23rd. Evercore ISI lifted their price objective on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the stock an “in-line” rating in a research note on Thursday, November 7th. William Blair downgraded shares of Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 22nd. Finally, Morgan Stanley lowered their target price on shares of Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating on the stock in a report on Wednesday, February 5th.

Charles River Laboratories International Trading Down 3.1 %

Shares of NYSE:CRL opened at $154.93 on Friday. Charles River Laboratories International has a 12-month low of $154.01 and a 12-month high of $275.00. The business has a 50 day moving average of $178.90 and a 200-day moving average of $192.24. The company has a quick ratio of 1.14, a current ratio of 1.48 and a debt-to-equity ratio of 0.61. The stock has a market cap of $7.92 billion, a PE ratio of 19.39, a P/E/G ratio of 6.47 and a beta of 1.37.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Wellington Management Group LLP lifted its holdings in shares of Charles River Laboratories International by 135,927.9% in the third quarter. Wellington Management Group LLP now owns 3,740,768 shares of the medical research company’s stock worth $736,819,000 after acquiring an additional 3,738,018 shares during the last quarter. Allspring Global Investments Holdings LLC increased its position in Charles River Laboratories International by 40.7% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,760,781 shares of the medical research company’s stock worth $346,821,000 after purchasing an additional 509,163 shares in the last quarter. Raymond James Financial Inc. bought a new position in Charles River Laboratories International in the 4th quarter valued at approximately $42,776,000. Cooke & Bieler LP boosted its position in Charles River Laboratories International by 42.1% in the fourth quarter. Cooke & Bieler LP now owns 426,767 shares of the medical research company’s stock valued at $78,781,000 after buying an additional 126,372 shares in the last quarter. Finally, Mizuho Securities USA LLC grew its stake in shares of Charles River Laboratories International by 2,336.4% during the third quarter. Mizuho Securities USA LLC now owns 96,871 shares of the medical research company’s stock worth $19,081,000 after buying an additional 92,895 shares during the last quarter. Institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).